AZN
AstraZeneca PLC
AZN's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AZN overall, supported by stronger modeled upside and stronger valuation.
AZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Healthy |
AZN's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AZN PE Valuation
AZN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AZN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for AZN, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $6.66 | +25% |
| Q1 2026 | $6.64 | +52% |
| Q4 2025 | $6.54 | +68% |
| Q3 2025 | $6.02 | +70% |
| Q2 2025 | $5.31 | +51% |
| Q1 2025 | $4.36 | +7.4% |
| Q4 2024 | $3.89 | +1.8% |
| Q3 2024 | $3.54 | -6.6% |
AZN earned $6.66 per share over the past year, up 25% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AZN on earnings, with more consistent year-over-year improvement.
AZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $15.4B | +6.4% |
| Q1 2026 | $15.3B | +13% |
| Q4 2025 | $15.5B | +4.1% |
| Q3 2025 | $15.2B | +12% |
| Q2 2025 | $14.5B | +12% |
| Q1 2025 | $13.6B | +7.2% |
| Q4 2024 | $14.9B | +24% |
| Q3 2024 | $13.6B | +18% |
AZN's revenue has grown year over year for 13 quarters in a row: $15.4B last quarter, up 6.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | -3.7 points |
| Q1 2026 | 28% | +0.7 points |
| Q4 2025 | 19% | +5.5 points |
| Q3 2025 | 24% | +8.1 points |
| Q2 2025 | 24% | +3.1 points |
| Q1 2025 | 27% | +2.5 points |
| Q4 2024 | 14% | +3.4 points |
| Q3 2024 | 16% | -1.5 points |
AZN's operating margin was 21% last quarter, down 3.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AZN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AZN on profitability, with a higher operating margin.
AZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.1B | +46% |
| Q1 2026 | $1.8B | -34% |
| Q4 2025 | $1.4B | -29% |
| Q3 2025 | $3.4B | +68% |
| Q2 2025 | $1.5B | -39% |
| Q1 2025 | $2.7B | +211% |
| Q4 2024 | $2B | +36% |
| Q3 2024 | $2B | -9.4% |
AZN generated $8.7B in free cash flow over the past year, up 6.8% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AZN on cash flow, with more consistent year-over-year improvement.
AZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -1M shares |
| 1 year | +0.1% | +1M shares |
| 3 years | 0% | -- |
| 5 years | +18% | +242M shares |
| Available history | +19% | +248M shares |
AZN has 1.6B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $46.3M |
| Q1 2026 | — |
| Q4 2025 | $198.8M |
| Q3 2025 | $12.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
AZN has spent almost nothing on buybacks in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.3x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | 1.7x | Healthy |
AZN's net debt is about 1.3 years of its operating earnings (EBITDA), down from 1.5 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over AZN on leverage, with a lower net debt burden relative to earnings.
AZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 85.9 | Overbought |
AZN's weekly RSI is 58 (neutral) and its Stochastic is 86 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AZN PE vs Healthcare Sector
| Metric | AZN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AZN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $172.1 | 7.1% above |
| 20 week MA | $169.4 | 8.9% above |
| 50 week MA | $181.2 | 1.8% above |
| 100 week MA | $165.1 | 12% above |
| 200 week MA | $153.4 | 20% above |
AZN is in an uptrend: it's above all five of its weekly moving averages, and 20% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
AZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $100.9 | $97.9 | -3% |
| 2021 | $97.9 | $115.0 | +18% |
| 2022 | $115.0 | $136.4 | +19% |
| 2023 | $136.4 | $134.4 | -1.4% |
| 2024 | $134.4 | $132.0 | -1.8% |
| 2025 | $132.0 | $181.3 | +37% |
| 2026 YTD | $181.3 | $184.4 | +1.7% |
AZN has finished lower in three of the last six years. It's up 1.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AZN on returns for 2026, with the stronger performance.